ClinicalTrials.gg
RecruitingNCT04029402Updated Apr 30, 2021

Molecular Analysis of Diabetic Kidney Disease Biopsies

An observational study in Diabetic Nephropathies and Kidney Disease, Chronic, sponsored by Unity Health Toronto. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.

Sponsored by Unity Health Toronto · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2022, 3 years 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Diabetic Nephropathies with a site in Canada — 5 open to participants now, 5 under way, 1 of them phase 3. Diabetic Nephropathies · Canada.

Started
2019
with 2 others
Observational
3 of 34
1 open now
Registered
23rd of 34
by date

Among the 34 studies in Diabetic Nephropathies with a site in Canada, this one is one of 3 that started in 2019, is one of 3 observational ones, and was the 23rd registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

5 of the 34 studies in Diabetic Nephropathies with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Diabetic Nephropathies with a site in Canada, or all of them as a file.
02

Study summary

Despite decades of research, the pathogenesis of human diabetic kidney disease remains largely unclear. Our goal is to use archived human kidney biopsy tissue from patients with and with diabetic nephropathy to identify new molecules that drive and/or protect against disease progression. We will use RNA sequencing to identify transcriptomic changes that associate with histologic and functional outcomes.

Read the detailed description

RESEARCH OBJECTIVES A. To identify differences in transcription profiles obtained from residual kidney tissue which was obtained for clinical purposes.

B. To identify differences in transcription profile between patients whose loss of kidney function progresses rapidly (eGFR decline ≥4ml/min/year) and in whom it progresses more slowly (eGFR decline \<4ml/min/year).

C. To identify differences in transcription profile between predominantly glomerular and predominantly tubulointerstitial histopathological types .

D. To identify new pathogenetic pathways that may become targets for therapeutic intervention

METHODS The planned study centres on the use of archival biopsy material that is superfluous to what is or would be needed for clinical care (01/01/1995 to 31/05/2018 , n= approximately 400-500). Archived samples will be collected from St. Michael's Hospital and a number of collaborating centres, including but not limited to University of British Columbia, the University of Manitoba, and the University of Ottawa.

RNA will be extracted from the biopsy material using either the core that has been used for immunofluorescence microscopy and is stored at -80˚C, and/or the core that is formalin-fixed, embedded in paraffin wax and stored at room temperature. The RNA thereby extracted will be subjected to detailed interrogation by RNASeq to quantify the expression level of mRNAs (transcriptome) and compare differences, as indicated in the research objectives detailed above. The transcriptome will then be related to the clinical course (eGFR decline) and histopathological changes, in addition to examining potentially pathogenetically important and that are amenable to therapeutic intervention.

Histopathology will also be performed and classified according to established systems.

Clinical information that would be retrieved from patients' medical records are listed below.

Clinical data

  1. Age
  2. Gender
  3. Ethnicity
  4. Diabetes history
  5. Diabetes type: 1, 2
  6. Retinopathy history
  7. Smoking history
  8. Medications
  9. Comorbidities
  10. Past medical history
  11. Primary nephrologist Laboratory data (prior to biopsy, at biopsy and post-biopsy)
  12. Renal function measures and calculations. For example:

    i. Serum creatinine, eGFR ii. Change in creatinine and eGFR iii. Urinary albumin:creatinine values and ratio (ACR) iv. Urine protein:creatinine values and ratio (PCR) v. Urinary protein excretion rate (UPEx) vi. Changes in ACR, PCR, UPEx

  13. Diabetes measures and calculations. Biopsy data
  14. Biopsy related data

Each site will locally maintain a confidential Master Linking Log.

De-identified data will be entered into a secure REDCap database that is hosted by St. Michael's Hospital.

03

Conditions studied

  • Diabetic Nephropathies
  • Kidney Disease, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

  1. Cases: A group of patients with diabetic kidney disease
  2. Controls: A group of healthy control patients

Eligibility criteria

Inclusion Criteria (diabetic kidney disease cases):

  • history of type 1 or type 2 diabetes
  • at least 1 archived native kidney that demonstrates either pure diabetic kidney disease or features of non-specific vascular disease, including glomerulosclerosis, non-inflammatory vascular disease,
  • sufficient remaining archived kidney biopsy tissue for RNA sequencing (100 um thick tissue section) and histologic analysis (PAS and Masson Trichrome staining)

Exclusion Criteria (diabetic kidney disease cases):

  • less than 3 values post-biopsy
  • latest recorded eGFR values less than 6 months post-biopsy

Inclusion Criteria (healthy controls):

  • at least 1 native kidney disease biopsy with no diagnostic abnormality
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Diabetic kidney disease

    Patients with archived biopsies with a pathologic diagnosis of diabetic kidney disease, interstitial fibrosis/tubular atrophy, or nephrosclerosis.

    Other: RNA sequencing

  • Healthy controls

    Potential living donors with archived biopsies performed as part of their donor workup and with no diagnostic abnormalities

    Other: RNA sequencing

Interventions

  • OtherRNA sequencing

    Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline

    Also known as: Histology, Slope of eGFR decline

06

What researchers measure

Primary outcomes

  1. Interstitial fibrosis

    Extent of interstitial fibrosis in kidney biopsy assessed using a semi-quantitative scale on light microscopy of biopsy sections

    Time frame: Baseline biopsy

  2. Glomerulosclerosis

    Extent of glomerulosclerosis in kidney biopsy assessed using a semi-quantitative scale on light microscopy of biopsy sections

    Time frame: Baseline biopsy

  3. Renal function change

    Slope of eGFR decline

    Time frame: Baseline biopsy

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2019 (actual). Primary completion is estimated for Dec 2022, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2019
First posted
Jul 23, 2019
StartActual
Jul 1, 2019
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2025
Last update
Apr 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04029402
Responsible party
Sponsor
First posted
Jul 23, 2019
Start date
Jul 1, 2019
Primary completion
Dec 2022 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 30, 2021

Study contacts

Richard Gilbert, MD PhD
Contact
richard.gilbert@utoronto.ca
416-864-3747

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion